Cantargia AB (SE0006371126) — research page
SE · se-cm-kg/XSTO/SE0006371126 · as of 2026-11-06
Identity and listing
The issuer is Cantargia AB, listed on Nasdaq Stockholm under ticker SE0006371126, with ISIN SE0006371126 and LEI 549300GKWRT7RXI4VS85. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Cantargia AB | source · 2026-11-06 |
| exchange | Nasdaq Stockholm | source · 2026-11-06 |
| ticker | SE0006371126 | source · 2026-11-06 |
| ISIN | SE0006371126 | source · 2026-11-06 |
| LEI | 549300GKWRT7RXI4VS85 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 34 filings across 31 filing days in the twelve months to 2026-11-06. The median gap between filing days is 9.0 days, and the latest filing is dated 2026-11-05, 1 day before the record date. The latest filing type is Investor News. The Nasdaq Stockholm peer medians are 9.5 days of cadence, 30.0 filings and 7.0 days of latency across 398 issuers. Sector peer figures are not on the record for this market.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 34 | 9 | 1 |
| exchange median: Nasdaq Stockholm (398 issuers) | 30 | 9.5 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | Investor News | Investor News | Cantargia to host Q3 2026 Interim Results Conference Call |
| 2026-11-04 | Inside information | Inside information | Cantargia Presents Promising Early Results with Nadunolimab in MDS and AML Ahead of ASH 2026 |
| 2026-10-29 | Other information disclosed according to the rules of the Exchange | Other information disclosed according to the rules of the Exchange | Cantargia presents Nomination Committee ahead of 2027 AGM |
| 2026-10-27 | Investor News | Investor News | Cantargia to Present at the Stifel 2026 Healthcare Conference |
| 2026-10-26 | Changes board/management/auditors | Changes board/management/auditors | Cantargia appoints Dr. Monic Stuart as Chief Medical Officer |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is not on the record, and neither is its location. The market's record does not carry auditor changes.
Events and halts
The record carries no listing, delisting, name change, domicile change or segment move lines, because the register has no lifecycle type map yet. The halt flag shows listed, not halted.
Orderability
The outcome is not determinable for this issuer. The orderability section of the chapter carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 4 research houses: DNB Carnegie, REDEYE, Van Lanschot Kempen and H.C. Wainwright.
| research house | analyst | source · read date |
|---|---|---|
| DNB Carnegie | Arvid Necander | issuer page · 2026-11-12 |
| REDEYE | Richard Ramanius | issuer page · 2026-11-12 |
| Van Lanschot Kempen | Sebastiaan van der Schoot | issuer page · 2026-11-12 |
| H.C. Wainwright | Sara Nik, Ph.D. and Joe Pantginis, Ph.D | issuer page · 2026-11-12 |
Open research
The record holds 8 openly published research notes. Redeye has published 4, Edison Investment Research Limited has published 3 and Nordea Markets has published 1. The most recent is dated 2025-02-24 and the earliest 2021-03-10.
| date | publisher | note | kind |
|---|---|---|---|
| 2025-02-24 | Redeye | Cantargia Q4 2024: Focus on Business Development | independent |
| 2023-10-31 | Redeye | Cantargia: Cash Runway Extended into 2025 | independent |
| 2023-02-24 | Redeye | Progress in Triple-Negative Breast Cancer | independent |
| 2023-01-16 | Redeye | Cantargia: Comments on CAN10’s toxicity study and the share price rally | independent |
| 2022-08-31 | Nordea Markets | Commissioned Equity Research | issuer-sponsored |
| 2022-08-31 | Edison Investment Research Limited | Cantargia | issuer-sponsored |
| 2022-05-24 | Edison Investment Research Limited | Cantargia | issuer-sponsored |
| 2021-03-10 | Edison Investment Research Limited | Cantargia | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, the market has no earliest sealed date, and the live record start is not on the record.
Sources
15 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/XSTO/SE0006371126 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://cantargia.com/en/investors/analyst-coverage (coverage)
- 10.7
- https://cantargia.com/assets/uploads/Redeye-Research-Update-250224.pdf (open research)
- 10.8
- https://cantargia.com/assets/uploads/Redeye-Research-Note-231031.pdf (open research)
- 10.9
- https://cantargia.com/assets/uploads/Redeye-Analysis-Cantargia-Q4-2022-230224.pdf (open research)
- 10.10
- https://cantargia.com/assets/uploads/Redeye-Research-Note-Cantargia-230116.pdf (open research)
- 10.11
- https://cantargia.com/assets/uploads/Nordea-Cantargia_Commissioned_Research_310822.pdf (open research)
- 10.12
- https://cantargia.com/assets/uploads/Edison-Analys-Cantargia-220831.pdf (open research)
- 10.13
- https://cantargia.com/assets/uploads/Edison-Analys-Cantargia-220524.pdf (open research)
- 10.14
- https://cantargia.com/assets/uploads/Edison-Analys-Cantargia-210310.pdf (open research)
- 10.15
- https://mcp.se-cm-kg.ai/record/XSTO/SE0006371126 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0006371126"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:7e92e7deb8474ce0.